Use of the Uricase-Inhibited Rat as an Animal Model in Toxicology

References

• Lindsey J., Capen C. C. Animal models for biomedical research VI—metabolic disease (symposium). Federation Proc. 1976; 35: 1192
   Google Scholar
• Animal Models for Biomedical Research, Symposia I, II, III and IV. Printing and Publishing Office, National Academy of Sciences, Washington, D.C. 20418
   Google Scholar
• Kumar R. Animal models for screening new agents: a behavioural view. Brit. J. Clin. Pharmacol. 1976; 13, (Suppl.)
   PubMed Web of Science ®Google Scholar
• Johnson W. J., Stavric B., Chartrand A. Uricase inhibition in the rat by s‐triazines: an animal model for hyperuricemia and hyperuricosuria. Proc. Soc. Exptl. Biol. Med. 1969; 131: 8
   PubMed Web of Science ®Google Scholar
• Stavric B., Johnson W. J., Grice H. C. Uric acid nephropathy: an experimental model. Proc. Soc. Exptl. Biol. Med. 1969; 130: 512
   PubMed Web of Science ®Google Scholar
• Smith L. H., Jr. Disorders of Purine Metabolism. Cecil‐Loeb, Textbook of Medicine13th ed., P. B. Beeson, W. McDermott. Saunders, Philadelphia 1971; 1682
   Google Scholar
• McLaughlin G. E., McCarty D. J., Jr., Prescott D. J. Gout and Hyperuricemia. Topics in Medicinal Chemistry, J. L. Rabinonitz, R. M. Myerson. Wiley (Interscience), New York 1970; Vol. 3: 263
   Google Scholar
• Seegmiller J. E., Laster L., Howell R. R. Biochemistry of uric acid and its relation to gout. New Engl. J. Med. 1963; 268: 712, 764, 821
   Web of Science ®Google Scholar
• Gutman A. B. Renal excretion of uric acid in normal and gouty man. Arthrit. Rheum. 1965; 8: 665
   PubMedGoogle Scholar
• Smyth C. J. Disorders associated with hyperuricemia. Arthrit. Rheumat. 1975; 18(Suppl. No. 6)713
   PubMed Web of Science ®Google Scholar
• Frank O. Observations Concerning the Incidence of Disturbance of Lipid and Carbohydrate Metabolism in Gout. Purine Metabolism in Man, O. Sperling, A. DeVries, J. B. Wyngaarden. Plenum, New York 1974; 495
   Google Scholar
• Pearce J., Aziz H. Uric acid and plasma lipids in cerebrovascular disease. Brit. Med. J., Part I 1969; 4: 78, prevalence of hyperuricemia
   PubMed Web of Science ®Google Scholar
• Gibson T., Grahame R. Gout and Hyperlipidaemia. Purine Metabolism in Man, O. Sperling, A. DeVries, J. B. Wyngaarden. Plenum, New York 1974; 499
   Google Scholar
• Lesch M., Nyhan W. L. A familial disorder of uric acid metabolism and central nervous system function. Am. J. Med. 1964; 36: 561
   PubMed Web of Science ®Google Scholar
• Mustard J. F., Murphy E. A., Ogryzlo M. A., Smythe H. A. Blood coagulation and platelet economy in subjects with primary gout. Canad. Med. Assoc. J. 1963; 89: 1207
   PubMed Web of Science ®Google Scholar
• Wallace S. L. Gout and hypertension. Arthritis Rheum. 1975; 18(Suppl. No. 6)721
   PubMed Web of Science ®Google Scholar
• Rakic M. T., Valkenburg H. A., Davidson R. T., Engels J. P., Mikkelsen W. M., Neel J. V., Duff I. F., Himes S. Observations on the natural history of hyperuricemia and gout. I. An eighteen year follow‐up of nineteen gouty families. Am. J. Med. 1964; 37: 862
   PubMed Web of Science ®Google Scholar
• Montoye H. J., Faulkner J. A., Dodge H. J., Mikkelsen W. M., Willis P. W., III, Block W. D. Serum uric acid concentration among business executives. Ann. Intern. Med. 1967; 66: 838
   PubMed Web of Science ®Google Scholar
• Van Peenen H. J. The causes of non‐azotemic hyperuricemia. Am. J. Clin. Pathol. 1971; 55: 698
   PubMed Web of Science ®Google Scholar
• McEwin R., McEwin K., Loudon B. Raised serum uric acid levels with myocardial infarction. Med. J. Australia 1974; 1: 530
   PubMed Web of Science ®Google Scholar
• Jacobs D. Hyperuricemia and myocardial infarction. S. Afr. Med. J. 1972; 46: 367
   PubMed Web of Science ®Google Scholar
• Kohn P. M., Prozan G. B. Hyperuricemia–relationship to hypercholesteremia and acute myocardial infarction. JAMA 1959; 170: 1909
   PubMed Web of Science ®Google Scholar
• Pochedly C. Hyperuricemia in leukemia and lymphoma. N.Y. State J. Med. 1973; 73: 1085
   PubMedGoogle Scholar
• Ultmann J. E. Hyperuricemia in disseminated neoplastic disease other than lymphomas and leukemias. Cancer 1962; 15: 122
   PubMed Web of Science ®Google Scholar
• Phoon W. H., Pincherle G. Blood uric acid in executives. Brit. J. Ind. Med. 1972; 29: 334
   PubMedGoogle Scholar
• Pfeiffer C. C., Iliev V., Nichols R. E., Sugerman A. A. The serum urate level reflects degree of stress. J. Clin. Pharmacol. 1969; 9: 384
   Web of Science ®Google Scholar
• Katz J. L., Weiner H., Gutman A., Yü T. ‐F. Hyperuricemia gout and the executive suite. JAMA 1973; 224: 1251
   PubMed Web of Science ®Google Scholar
• Schrier R. W., Hano J., Keller H. I., Finkel R. M., Gilliland P. F., Cirksena W. J., Teschon P. E. Renal, metabolic and circulatory responses to heat and exercise. Ann. Intern. Med. 1970; 73: 213
   PubMed Web of Science ®Google Scholar
• Emmerson B. T., Douglas W., Doherty R. L., Feigl P. Serum urate concentrations in the Australian aboriginal. Ann. Rheum. Dis. 1969; 28: 150
   PubMed Web of Science ®Google Scholar
• Healey L. A. Epidemiology of hyperuricemia. Arthritis Rheum. 1975; 18(Suppl. No. 6)709
   PubMed Web of Science ®Google Scholar
• Kasl S. V., Brooks G. W., Rodgers W. L. Serum uric acid and cholesterol in achievement behaviour and motivation I. JAMA 1970; 213: 1158
   PubMed Web of Science ®Google Scholar
• Editorial, Uric acid and the psyche. JAMA 1969; 208: 1180
   Web of Science ®Google Scholar
• Lanese R. R., Gresham G. E., Keller M. D. Behavioral and physiological characteristics in hyperuricemia. JAMA 1969; 207: 1878
   PubMed Web of Science ®Google Scholar
• Kennett K. F., Cropley A. J. Uric acid and divergent thinking: a possible relationship. Brit. J. Psychol. 1975; 66: 175
   PubMed Web of Science ®Google Scholar
• Cristofori F. C., Duncan G. G. Uric acid excretion in obese subjects during periods of total fasting. Metabolism 1964; 13: 303
   PubMed Web of Science ®Google Scholar
• Klinenberg J. R., Gonick H. C., Dornfeld L. Renal function abnormalities in patients with asymptomatic hyperuricemia. Arthritis Rheum. 1975; 18(Suppl. No. 6)725
   PubMed Web of Science ®Google Scholar
• Scott J. T. Causes of hyperuricemia. Proc. Roy. Soc. Med. 1969; 62: 19
   PubMedGoogle Scholar
• Zöllner N., Griebsch A. Diet and Gout. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 435
   Google Scholar
• Griebsch A., Zöllner N. Effect of Ribomononucleotides Given Orally on Uric Acid Production in Man. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 443
   Google Scholar
• Zöllner N., Diet, Gout (1975) Proc. 9th Int. Congr. Nutrition. Mexico, 1972. 1: 267
   Google Scholar
• Clifford A. J., Riumallo J. A., Young V. R., Scrimshaw N. S. Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. J. Nutr. 1976; 106: 428
   Web of Science ®Google Scholar
• Bell J. D., Margen S., Galloway D. H. Ketosis, weight loss, uric acid and nitrogen balance in obese women fed single nutrients at low caloric levels. Metabolism 1969; 18: 193
   PubMed Web of Science ®Google Scholar
• Drenick E. J., Swenseid M. E., Blahd W. H., Tuttle S. G. Prolonged starvation as treatment for severe obesity. JAMA 1974; 187: 100
   Google Scholar
• Lloyd‐Mostyn R. H., Lord P. S., Glover R., West C., Gilliland I. C. Uric acid metabolism in starvation. Ann. Rheum. Dis. 1970; 29: 553
   PubMed Web of Science ®Google Scholar
• Fox I. H., Kelly W. N. Studies on the mechanism of fructoseinduced hyperuricemia in man. Metabolism 1972; 21: 713
   PubMed Web of Science ®Google Scholar
• Schwarzmeier J. D., Marktl W., Moser K., Lujf A. Fructoseinduced hyperuricemia. Res. Exptl. Med. 1974; 162: 341
   PubMed Web of Science ®Google Scholar
• Kelly W. N. Effects of drugs on uric acid in man. Ann. Rev. Pharmacol. 1975; 15: 327
   PubMedGoogle Scholar
• Krakoff C. H. Clinical pharmacology of drugs which influence uric acid production and excretion. Clin. Pharmacol. The rap. 1967; 8: 124
   PubMed Web of Science ®Google Scholar
• Weiner I. M. Comparative pharmacology of uricosuric drugs. Gen. Pharmacol. 1976; 7: 1
   PubMedGoogle Scholar
• Fanelli G. M., Jr. Uricosuric agents. Arthritis Rheum. 1975; 18(Suppl. No. 6)853
   PubMed Web of Science ®Google Scholar
• Emmerson B. T. Hyperuricaemia—to treat or not?. Drugs 1975; 9: 141
   PubMed Web of Science ®Google Scholar
• Wacker W. E. C. Man: sapient but gouty. New Engl. J. Med. 1970; 283: 151
   PubMed Web of Science ®Google Scholar
• Fanelli G. M., Jr., Beyer K. H., Jr. Uric acid in non‐human primates with special reference to its renal transport. Ann. Rev. Pharmacol. 1974; 14: 355
   Google Scholar
• Duncan H., Wakim K. G., Ward L. E. The effects of intravenous administration of uric acid on its concentration in plasma and urine of Dalmatian and non‐Dalmatian dogs. J. Lab. Clin. Med. 1961; 58: 876
   PubMed Web of Science ®Google Scholar
• Kuster G., Shorter R. G., Dawson B., Hallenbeck G. A. Uric acid metabolism in Dalmatians and other dogs. Arch. Int. Med. 1972; 129: 492
   PubMed Web of Science ®Google Scholar
• Mudge G. H., Cucchi J., Platts M., O'Connell J. M. B., Berndt W. O. Renal excretion of uric acid in the dog. Am. J. Physiol. 1968; 215: 404
   PubMed Web of Science ®Google Scholar
• Berger L., Yü T ‐F. Urinary excretion of uric acid after instantaneous intra‐renal‐arterial injection in mongrel and Dalmatian dogs. J. Mount Sinai Hosp. 1970; 37: 351
   Google Scholar
• Austic R. E., Cole R. K. Impaired renal decrease of uric acid in chickens having hyperuricemia and articular gout. Am. J. Physiol. 1972; 223: 525
   PubMed Web of Science ®Google Scholar
• Fitzgerald T. J. Anti‐inflamatory Agents, Chemistry and Pharmacology, R. A. Schener, M. W. Whitehouse. Academic, New York 1974; Vol. 1: 302
   Google Scholar
• Grims W. A. A phase contrast study of the mechanisms of renal calcification. J. Urol. 1957; 78: 553
   PubMed Web of Science ®Google Scholar
• Duncan H., Wakim K. G., Ward L. E. Renal lesions resulting from induced hyperuricemia in animals. Mayo Clinic Proc. 1963; 38: 411
   Web of Science ®Google Scholar
• Smith J. F., Lee Y. C. Experimental uric acid nephritis in the rabbit. J. Exptl. Med. 1957; 105: 615
   PubMed Web of Science ®Google Scholar
• Dunn J. S., Poison C. J. Experimental uric acid nephritis. J. Pathol. Bacteriol. 1926; 29: 337
   Google Scholar
• Fridovich I. The competitive inhibition of uricase by oxonate and by related derivatives of s‐triazines. J. Biol. Chem. 1965; 240: 2491
   PubMed Web of Science ®Google Scholar
• Hatfield P. J., Simmonds H. A., Cameron J. S., Jones A. S., Cadenhead A. Effects of Allopurinol and Oxonic Acid on Pyrimidine Metabolism in the Pigs. Purine Metabolism in Man, O. Sperling, A. De Vries, J. B. Wyngaarden. Plenum, New York 1974; 637
   Google Scholar
• Gralla E. J., Crelin E. S., Osbaldiston G. W. The embryotoxic effects of a uricase inhibitor and i.v. sodium urate in rats and mice. Teratology 1975; 11: 19A
   Google Scholar
• Redman C. W. G., Beilin L. J., Bonnar J., Wilkinson R. H. Plasma‐urate measurements in predicting fetal death in hypertensive pregnancy. Lancet 1976; 1: 1370
   PubMed Web of Science ®Google Scholar
• Wildman R. A., Philp R. B. Effect of allopurinol on platelets and uric acid in oxonate‐induced hyperuricemic rabbits. Proc. Canad. Federation Biol. Sci. 1970; 13: 9
   Google Scholar
• Yü T. F., Gutman A., Berger L., Kaung C. Low uricase activity in the Dalmatian dog simulated in mongrels given oxonic acid. Am. J. Physiol. 1971; 220: 973
   PubMed Web of Science ®Google Scholar
• Stavric B., Nera E. A., Johnson W. J., Salem F. A. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Invest. Urol. 1973; 11: 3
   PubMedGoogle Scholar
• Waisman J., Bluestone R., Klineberg J. R. A preliminary report of nephropathy in hyperuricemic rats. Lab. Invest. 1974; 30: 716
   PubMed Web of Science ®Google Scholar
• Lindy S., Pakarinen A. Oxonate‐induced hyperuricemia and renal accumulation of uric acid in the rat. Scand. J. Clin. Lab. Invest. 1970; 25(Supp. 113)76
   Google Scholar
• Mwasi L. M., Waisman J., Bluestone R., Klinenberg J. R. A brief note on the ultrastructure of renal glomeruli in acutely hyperuricemic rats. Invest. Urology 1976; 13: 321
   PubMedGoogle Scholar
• Stavric B., Johnson W. J., Clayman S., Gadd R. E. A., Chartrand A. Effect of fructose administration on serum levels in the uricase inhibited rat. Experientia 1976; 32: 373
   PubMedGoogle Scholar
• Boda D., Penzes P., Gecse A., Streitmann K., Zsilinszky E., Karady I. Renal tubular necrosis after gastroenteritis in infants. Brit. Med. J. 1971; 1: 609
   PubMed Web of Science ®Google Scholar
• Boda D., Penzes P., Gesce A., Streitman K., Zsilinszky E., Karady I. Can. J. Physiol. Pharmacol. 1973; 151: 496
   Web of Science ®Google Scholar
• Bonardi G., Vidi A. Action of 4‐prenyl‐1,2‐diphenyl‐3, 5‐pyrazolidinedione (DA 2370) on an experimental hyperuricosuria in the rat. Pharm. Res. Commun. 1973; 5: 125
   Google Scholar
• Norrlind B., Kihlberg R. A short assay for the estimation of dietary purine compounds using a rat model system with inhibition of uricase. J. Nutr. 1973; 103: 1262
   PubMed Web of Science ®Google Scholar
• Lussier A., De Medicis R. Inhibition of adjuvant‐induced arthritis in hyperuricemic rats. Scand. J. Rheumat. June 1–7, 1975, Suppl. 8, VIII Europ. Rheumat. Congress, Helsinki, Abst. 129
   Google Scholar
• Waisman J., Mwasi L. M., Klinenberg J. R. Acute hyperuricemic nephropathy in rats. An electron microscopic study. Am. J. Pathol. 1975; 81: 367
   PubMed Web of Science ®Google Scholar
• Norrlind B., Kihlberg R. (1975) Plasma uric acid levels in rats given uricase inhibitor. Proc. 9th Int. Congr. Nutrition. 1972. Mexico, 3: 97
   Google Scholar
• Bluestone R., Waisman J., Klinenberg J. R. Chronic experimental hyperuricemic nephropathy; Biochemical and morphologic characterization. Lab. Invest. 1975; 33: 273
   PubMed Web of Science ®Google Scholar
• Bergmann F., Kwietny‐Govrin H., Ungar‐Waron H., Kalmus A., Tamari M. Relation of structure to the inhibitory activity of purines against urate oxidase. Biochem. J. 1963; 86: 567
   PubMed Web of Science ®Google Scholar
• Iwata H., Yamamoto I., Gohda E., Morita K., Nishino K. Effects of 5‐diazoimidazole‐4‐carboxamide and 3‐diazopyrasole‐4‐carboxamide and related thioazo compounds on xanthine oxidase, uricase and hypoxanthine‐guanine phosphoribosyltransferase. Biochem. Pharmacol. 1972; 21: 2141
   PubMed Web of Science ®Google Scholar
• Iwata H., Yamamoto I., Gohda E., Morita K., Nakamura M., Sumi K. Potent competitive uricase inhibitors—2,8‐diazohypoxanthine and related compounds. Biochem. Pharmacol. 1973; 22: 2237
   PubMed Web of Science ®Google Scholar
• Moore F. J., Thomas R. M. Allantoxanic acid as an oxidation product of uric acid. J. Am. Chem. Soc. 1918; 40: 1120
   Google Scholar
• Venable C. S. The action of hydrogen peroxide upon uric acid. J. Am. Chem. Soc. 1918; 40: 1099
   Google Scholar
• Handschumacher R. E. 5‐azaorotic acid and related inhibitors of the synthesis de novo of pyrimidine nucleotides. Cancer Res. 1963; 23: 634
   PubMed Web of Science ®Google Scholar
• Granat P., Creasey W. A., Calabresi P., Handschumacher R. E. Investigation with 5‐azaorotic acid, an inhibitor of the biosynthesis of pyrimidines de novo. Clin. Pharm. Therap. 1965; 6: 436
   PubMed Web of Science ®Google Scholar
• Čihak A., Šorm F. Metabolic transformations of 5‐azauracil and 5‐azaorotic acid in mouse liver and Escherichia coli. Effect on the synthesis of pyrimidines. Biochem. Pharmacol. 1972; 21: 607
   PubMed Web of Science ®Google Scholar
• Biltz H., Robl R. Elucidation of oxonic acid. Ber. 1920; 53B: 1967, ref. Chem. Abstr. 15, 1028 (1921) Elucidation of some transformations of oxonic acid and of allantoxaidine, Ber. 54B, 2441 (1921) ref. Chem. Abstr. 16, 1213 (1922)
   Google Scholar
• Canellakis E. S., Cohen P. P. On the nature of oxonic acid and allantoxaidin as oxidation products of uric acid and allantoin. J. Biol. Chem. 1955; 213: 379
   PubMed Web of Science ®Google Scholar
• Brandenberger H. The oxidation of uric acid to oxonic acid (allantoxanic acid) and its application in tracer studies of uric acid biosynthesis. Biochem. Biophys. Acta 1954; 15: 108
   PubMed Web of Science ®Google Scholar
• Hartman S. C., Fellig J. On the mechanism of the oxidation of uric acid by alkaline peroxidase. J. Am. Chem. Soc. 1955; 77: 1051
   Web of Science ®Google Scholar
• Aldrich Handbook of Organic Chemicals. Aldrich Chemical, Milwaukee 1972; 483
   Google Scholar
• Neville G. A., Stavric B., Swift P., to be published
   Google Scholar
• Barlow K. A., Beilin L. J. Renal disease in primary gout. Quart. J. Med. 1968; 37: 79
   PubMedGoogle Scholar
• Bluestone R., Brady S., Waisman J., Klinenberg J. Experimental hyperuricemic nephropathy. Arthritis Rheumat. 1975; 18(Suppl. No. 6)823
   PubMed Web of Science ®Google Scholar
• Stavric B., Nera E. A. 1972, unpublished observations
   Google Scholar
• Stavric B., Nera E. A., Clayman S., Gadd R. E. A., Hebert D. Effect of acute hyperuricemia on selected blood parameters and reversible nephrotoxicity due to elevated uric acid in the rat. Soc. Exptl. Biol. Med., 3rd Sci. Meeting, Champlain Section, Nov. 17, 1973, Burlington, Vermont. Part of this report was already published (see Ref. ‘110’). The manuscript on reversible nephrotoxicity is in preparation
   Google Scholar
• Nera E. A., Stavric B. Necrotic effect of urate on glomeruli in the rat kidney induced by potassium oxonate (Preliminary observations). Soc. Exptl. Biol. Med., 7th Sci. Meeting, Champlain Section, Nov. 15, 1975, Burlington, Vermont (to be published)
   Google Scholar
• Editorial, Hyperuricemic acute renal failure. Lancet 1974; 1: 1266
   PubMed Web of Science ®Google Scholar
• Warren D. J., Leitch A. G., Leggett R. J. E. Hyperuricemic acute renal failure after epileptic seizures. Lancet 1975; 2: 385
   PubMed Web of Science ®Google Scholar
• Klinenberg J. R., Kippen I., Bluestone R. Hyperuricemic nephropathy: Pathologic features and factors influencing urate deposition. Nephron 1975; 14: 88
   PubMed Web of Science ®Google Scholar
• Stavric B., Johnson W. J. the Proceedings of the Canad. Federation Biol. Soc. Vol. 12, 12th Ann. Meeting, Edmonton, Alberta, June, 11‐13th1969, unpublished observations as reported in
   Google Scholar
• Scott J. T., O'Brien P. K. Probenecid, nephrotic syndrome and renal failure. Ann. Rheum. Dis. 1968; 27: 249
   PubMed Web of Science ®Google Scholar
• Bianchi C., Bonardi G. Pharmacological investigations of 4‐prenyl‐1,2‐diphenyl‐3, 5‐pyrazolidinedione (DA 2370). Arzneimittel‐Forsch. 1972; 22: 196
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. M., Goldstein J. L., Kelly W. N. Prolonged hyperuricemia associated with acute chlorprothixene ingestion. Arthritis Rheum. 1975; 18(Suppl. No. 6)739
   PubMed Web of Science ®Google Scholar
• Healey L. A., Harrison M., Decker J. L. Uricosuric effect of chlorprothixene. New Engl. J. Med. 1964; 272: 526
   Web of Science ®Google Scholar
• Karn W. N., Mead B. T., Fishman J. J. Double‐blind study of chlorprothixene (Taractan) a panpsychotropic agent. J. New Drugs 1961; 1: 72
   Google Scholar
• Council on Drugs, Evaluation of chlorprothixene (Taractan). JAMA 1963; 186: 144
   PubMed Web of Science ®Google Scholar
• Stavric B., Clayman S., Gadd R. E. A., Hebert D. Some in vivo effects in the rat induced by chloroprothixene and potassium oxonate. Pharm. Res. Commun. 1975; 7: 117
   PubMedGoogle Scholar
• Gutman A. B. Uricasuric drugs with special reference to probenecid and sulfinpyrazone. Advan. Pharmacol. 1966; 4: 91
   PubMedGoogle Scholar
• Shapiro D. M., Shils M. E., Fugmann R. A., Friedland L. M. Quantitative biochemical differences between tumor and host as a basis for cancer chemotherapy. IV. Niacin and 2‐ethylamino‐1,3, 4‐tiadiazole. Cancer Res. 1957; 17: 29
   PubMed Web of Science ®Google Scholar
• Krakoff I. H., Magill G. B. Effects of 2‐ethylamino‐1,3, 4‐HC1 on uric acid production in man. Proc. Soc. Exptl. Biol. Med. 1956; 91: 470
   PubMed Web of Science ®Google Scholar
• Stavric B., Johnson W. J., Chartrand A. Effect of some diuretics on hyperuricemic rats. 1972, unpublished observations
   Google Scholar
• Postlethwaite A. E., Kelley W. N. Uricosuric effect of radiocontrast agents. Ann. Intern. Med. 1971; 74: 845
   PubMed Web of Science ®Google Scholar
• Emmerson B. T. Effect of oral fructose on urate production. Ann. Rheum. Dis. 1974; 33: 276
   PubMed Web of Science ®Google Scholar
• Stirpe F., Della Corte E., Bonetti E., Abbondanza A., Abbati A., de Stefano F. Fructose‐induced hyperuricemia. Lancet 1970; 2: 1310
   PubMed Web of Science ®Google Scholar
• Heuckenkamp P. U., Zöllner N. Fructose‐induced hyperuricemia. Lancet 1971; 1: 808
   PubMed Web of Science ®Google Scholar
• Simkin P. A. Hexose infusions in Cebus monkeys: effects on uric acid metabolism. Metabolism 1972; 21: 1029
   PubMed Web of Science ®Google Scholar
• Robinson J. W., Food Technicol Service Staff. Food Engineering. May, 1975; 57
   Google Scholar
• Food Engineering. May, 1975; 55, Research Report, Food sweeteners enter a new era
   Google Scholar
• MacLaughlan M. J., Rodnan G. P. Effects of food, fast and alcohol on serum uric acid and acute attacks of gout. Am. J. Med. 1967; 42: 38
   PubMed Web of Science ®Google Scholar
• Newcombe D. S. Ethanol metabolism and uric acid. Metabolism 1972; 21: 1193
   PubMed Web of Science ®Google Scholar
• Healey L. A. Port wine and the gout. Arthritis Rheum. 1975; 18(Suppl. No. 6)659
   PubMed Web of Science ®Google Scholar
• Yü T. F., Sirota J. H., Berger L., Halpern M., Gutman A. B. Effect of sodium lactate infusion on urate clearance in man. Proc. Soc. Exptl. Biol. Med. 1957; 96: 809
   PubMed Web of Science ®Google Scholar
• Gömöri P., Zolnai B., Nagy Z., Jakab I. The problem of renal ischemia and of the arterio‐venosus anastomoses of the kidney. Acta Med. Acad. Sci., Hung. 1964; 20: 169
   PubMedGoogle Scholar
• Balint P., Fekete A., Szalay E., Taraba I. The effect of anaesthesia on the course of acute renal failure. Naunym‐Schmiedelberg. Arch. Exptl. Pathol. Pharmakol. 1960; 239: 497
   PubMedGoogle Scholar
• Herz R., Sauter V., Bircher J. Fortuitous discovery of urate nephrolithiasis in rats subjected to portacaval anastomosis. Experientia 1972; 28: 27
   PubMedGoogle Scholar
• Henderson J. F. Purine metabolism and human disease. Clin. Biochem. 1969; 2: 241
   Web of Science ®Google Scholar
• Boyd E. M., Dolman M., Knight L. M. The chronic oral toxicity of caffeine. Can. J. Physiol. Pharmacol. 1965; 43: 995
   Web of Science ®Google Scholar
• Solyom L., Enesco H. E., Beaulieu C. The effects of RNA, uric acid and caffeine on conditioning and activity in rats. J. Psychiat. Res. 1968; 6: 175
   PubMed Web of Science ®Google Scholar
• Newland H. Antagonism of the anti‐thrombotic effect of Warfarin by uric acid. Am. J. Med. Sci. 1968; 256: 44
   PubMed Web of Science ®Google Scholar
• Dreyfuss F., Zahavi J. Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease. Atherosclerosis 1973; 17: 107
   PubMed Web of Science ®Google Scholar
• Elion G. B., Bieber S., Nathan H., Hitchings G. H. Uracil antagonism and inhibition of mammary adenocarcinoma 755. Cancer Res. 1958; 18: 802
   PubMed Web of Science ®Google Scholar
• Čihak A., Šorm F. Metabolic transformations of 5‐azaorotate: Cause of marked inhibition of orotidine‐5′‐phosphate decarboxylase. Biochim. Biophys. Acta 1967; 149: 314
   PubMed Web of Science ®Google Scholar
• Rubin R. J., Reynard A., Handschumacher R. E. An analysis of the lack of drug synergism during sequential blockade of de novo pyrimidine biosynthesis. Cancer Res. 1964; 24: 1002
   PubMed Web of Science ®Google Scholar
• Stevens H. A. A multi‐disciplinary catalogue of uric acid. Perceptual and Motor Skills 1973; 36: 1007
   PubMed Web of Science ®Google Scholar